top of page
OUR SPEAKERS
Larry Hsu 許中強
Chairman & CEO, Lifemax Healthcare International Corporation
Dr. Larry Hsu is currently the Co-Founder, Chairman & CEO of Lifemax Healthcare International Corporation with primary focus on developing new drugs in the CNS area. Lifemax Healthcare International Corporation was founded in later 2014 with two wholly-owned subsidiaries: Lifemax Laboratories, Inc. in U.S. and Lifemax Biotechnology, Inc. in Taiwan.
Prior to Lifemax, Dr. Hsu was the President and CEO of Impax Laboratories, a Nasdeq-listed specialty pharmaceutical company co-founded by him and a partner. Impax’s business objective is applying its formulation, clinical development expertise and drug delivery technology to the development, manufacturing and distribution of controlled-release and specialty generics and branded prescription drugs. In the 18 years of its history, Impax Laboratories grew to a company with more than 1000 employees and a market cap of almost $3 billion USD. Dr. Hsu retired from Impax in April 2014.
Dr. Hsu received his Ph.D. degree in Pharmaceutics from University of Michigan. He worked at Abbott laboratories for 15 years. During the last four years at Abbott, Dr. Hsu was the Director of Product Development in charge of worldwide product development, process engineering, clinical supplies manufacturing and production technical support of all dosage forms. Dr. Hsu received his B.S. degree in Pharmacy from National Taiwan University.
Kuen-Yuh Wu 吳焜裕
Legislator, Taiwan;
Social Welfare and Environmental Hygiene Committee;
Professor, Institute of Occupational Medicine and Industrial Hygiene
Born and grown up in Chiayi, Dr. Kuen-Yuh Wu received his BS degree from National Tsin-Hua University, Taiwan, MS from National Yang-Ming University, MS and PhD from University of North Carolina at Chapel Hill. He pursued his academic career in Taiwan, and now brings his expertise to Legislative Yuan. His research interests have been to develop mass spectrometer methods to quantitate metabolites, DNA and protein adducts for humans exposed to carcinogens, and to conduct health risk assessment in foods, workplaces, and environments. He is devoted to promote food safety assessment, management, and communication in Taiwan.
LOUISE T. CHOW 周芷
Professor, Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham
Born in Hunan, China, Louise T. Chow received BS from National Taiwan University, PhD from Caltech (1973), and post‐doctoral training at UCSF. She joined Cold Spring Harbor Laboratory as a fellow (1975), where she deciphered the structures of adenovirus mRNAs and is the first author on a report describing RNA splicing (1977), the foundation of modern medicine. The 1993 Nobel Prize in Physiology or Medicine was awarded to her collaborator. She was tenured in 1979. At University of Rochester (1984‐ 1993), she initiated human papillomaviruses research and has been continuing these studies as Professor of Biochemistry and Molecular Genetics at University of Alabama at Birmingham.
Chou-Long Huang 黃朝榮
Professor, Internal Medicine
Jacob Lemann, M.D. Professorship in Calcium Transport;
Ruth W. and Milton P. Levy, Sr. Chair in Molecular Nephrology
University of Texas Southwestern Medical Center
Dr. Huang is Ruth W. and Milton P. Levy, Sr. Chair in Molecular Nephrology; Jacob Lemann Professor of Internal Medicine at University of Texas Southwestern Medical Center. He graduated from Taipei Medical University in Taipei, Taiwan in 1981, received a PhD in Physiology at UCSF in 1989, completed internal medicine residency in the University of Iowa Hospitals in 1992, and renal fellowship at UCSF in 1996. He joined UT Southwestern as assistant professor of internal medicine in 1996 and rose to the rank of tenured full professor in 2006. He is a physician scientist who maintains an active general nephrology practice and also directs NIH-funded research laboratory. His research interests include molecular mechanism of hypertension and pathogenesis of cardiac hypertrophy in chronic kidney disease patients.
Diane D-S. Tang-Liu 湯丹霞
Co-Founder and CEO, AiViva BioPharma.
Co-Founder, Allgenesis, Inc.
CEO & President, DTL BioPharma Consulting
Diane Tang-Liu is the Co-Founder and CEO of AiViva BioPharma focusing on drug development in dermatology, ophthalmology and urology. She also heads up DTL BioPharma Consulting, Inc., which provides strategic advice, operational expertise, and consulting services to biotechnology and pharmaceutical companies. Diane has co-founded Allgenesis, Inc. (新源生物科技), which develops NCEs and therapeutic proteins for global markets. She has 30 years of experience in pharmaceutical development with Allergan, Inc., and spent over 20 years in R&D executive and portfolio management.
Dr. Tang-Liu is a full adjunct professor of Pharmacology and Pharmaceutical Sciences at the University of Southern California, and of Bioengineering and Therapeutic Sciences at the University of California, San Francisco. Diane was elected AAPS Fellow and ACCP Fellow. Diane received B.S. in Pharmacy from National Taiwan University, and Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco.
Joshua C. Chang 張家晞
Postdoctoral Researcher in Molecular Biology, Genentech
I thrive by working both in matrix and independent environments and want to apply my scientific knowledge and work ethic to a career in biomedical/pharmaceutical setting. I have accomplished various projects in different fields of biology, including ecology and physiology during my undergrad in National Chung Hsing University, and learned molecular biology while obtaining my Master of Science degree at National Taiwan University/Academia Sinica. In order to broaden my perspective and improve my knowledge, I decided to pursue my PhD in America. I studied neuroscience and embryonic development in UT Southwestern Medical Center at Dallas. After graduation, I was eager for more stimulation and motivation in science. I wanted to be involved in drug development pipeline in the industry. I am currently working as a postdoc in Genentech, investigating on metabolic disease.
Yu-Chieh (Jack) Wang 王昱捷
Assistant Professor, Department of Pharmaceutical Sciences, University of North Texas Health Science Center (UNTHSC)
Dr. Yu-Chieh (Jack) Wang received his doctoral degree in medicinal chemistry and pharmacognosy from the Ohio State University. His previous research was focused on the experimental therapeutics of human cancer and the regulation of kinase signaling using novel small-molecules. Prior to joining UNTHSC, Dr. Wang was a Senior Research Associate at the Scripps Research Institute (TSRI; La Jolla, CA) and led several studies at the interface between cancer and stem cell biology with particular emphases on post-translational modification-mediated regulatory mechanisms underlying cellular pluripotency and the physio-pathological development of human pigment cells.
Dr. Wang currently holds a tenure-track faculty position at UNTHSC where he leads a group of highly motivated, young researchers seeking to break the mold of a traditional approach to biomedical research. Through the use of stem cells and the study of regenerative medicine, they strive to have a better understanding of how we can use these novel approaches to model or treat disease. The primary research focus in Wang lab is translational medicine aiming to understand the molecular basis of therapeutic responses in melanoma and to develop better strategies for managing cancer patients. In addition, there is a long-standing expertise and interest in the lab to study how protein modifications contribute to the regulation of stem cell differentiation and the developmental abnormalities in pediatric patients.
Tiencheng Arthur Chang
Associate Professor, Dept. of OB/GYN,
Director, Clinical Assisted Reproductive Technology Labs,
University of Texas Health Science Center at San Antonio
Dr. Chang obtained his BS degree in Animal Science from National Taiwan University, MS and PhD in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison, and clinical laboratory director/consultant board certification from American Board of Bioanalysis (ABB). His clinical and research interests include reproductive medicine, in vitro fertilization (IVF), embryology, preimplantation genetic diagnosis (PGD), embryo implantation, stem cell, laboratory quality management and regulatory compliance, healthcare business, as well as nonhuman primate animal models for reproductive and regenerative medicine. He has served on boards and committees of various academic associations and professional societies, and currently as President-Elect of Society of Reproductive Biologists and Technologists (SRBT). We believe that Dr. Chang’s profound expertise in laboratory medicine and experience in research make him an excellent role model for young professionals to develop their career in translational medicine.
Haofan (Eric) Peng 彭浩帆
Senior Engineer, Biogen Idec
Haofan Peng (Eric) is a senior engineer in the Manufacturing sciences group at Biogen. Prior to current position he was studying process design in cell culture development. In Biogen, he is the team manager in biologics process development including protein and antibody targeting at Multiple Sclerosis, Hemophilia, and Alzheimer. His main role is to support large scale manufacture in clinical and commercial campaign (2000L to 15,000L) as well as next generation world-class facility design focusing on continuous perfusion process. He also leads multiple cross functional projects including cell line evaluation, medium optimization, process development, filtration integration and instrument automation. Aside from lab he also works closely with GMP manufacture facility in RTP (NC) and Hillerod (Denmark). He published several papers in raw material screening and analytical assay development where he collaborates with groups in analytical development, quality control, regulatory, supply chain, procurement and multiple external biotech companies/vendors. Eric obtained his chemical engineering BS degree at National Taiwan University and PhD from the SUNY Buffalo in chemical and biological engineering where he focused on regenerative medicine and preclinical animal model.
Ian Y. Lian
Assistant Professor, Department of Biology, Lamar University
Dr.Lian conducted his undergraduate study in engineering physics and bioengineering, and mentored by Dr.Shu Chien during his graduate study in UCSD. To compliment his training in the engineering field, Dr.Lian receives his postdoc apprenticeship under Dr.Kun-Liang Guan in the area of cancer and stem cell biology. As an independent investigator at Lamar University, Dr.Lian combines basic science and engineering approaches to study the effect of microenvironment on the metastatic potential of cancer cells. In addition, his lab collaborated with teams of several biotech startups to develop amplification-free molecular as well as portable cellular detection platforms for biomedical and environmental science applications.
Wei-Chiang Chen
Scientist, ImmunoGen, Inc.
I am currently a scientist leading a small group focusing on high throughput assay development in ImmunoGen, Inc. My company focuses on developing immunotherapies in cancer. Before joining ImmunoGen, Inc., I was a scientist in Biogen. I received my MS in Chemical Engineering from University of Florida and my PhD in Chemical and Biomolecular Engineering from Johns Hopkins University. My expertise is in cell biology, oncology, high throughput assay development, and automation.
Mark (Long-Rong) Kao 高龍榮
Scientific Director,
Preclinical Development and Safety, Janssen Pharmaceutical R&D (J&J)
Mark (Long-Rong) Kao was born in Taipei, Taiwan. He studied at National Chung-Hsing University majoring in Entomology and Pesticide Toxicology. In 1979 he moved to US studying at North Carolina State University where he earned his Ph.D in Toxicology. After graduation he worked at NIEHS and Cornell University as a research fellow studying Mechanism of Toxicity. He later joined Bayer and Wyeth focusing on studies to address safety related issues for pesticides and animal health products. Since 2001 he has been working on preclinical and clinical safety evaluations of bio-pharmaceuticals at Janssen Pharmaceutical R&D (a subsidiary of J&J)
Henry C. Liu
Special Assistant, Lihpao Life Corp.
Henry C. Liu, PhD, works at Lihpao Life Corp., serving as the special assistant to CEO. As a project manager of clinical sequencing service and new drug development, he carries out several projects related to using genomic sequencing platform to identify biomarkers associated with disease prognosis, treatment outcome, and drug resistance. In the new drug development, he helps developing a platform for drug delivery, which is used to target against cancer and enzyme-deficient diseases with a cost-effective and oral delivery.
Henry Liu completed his Ph.D. in Bioengineering at UCSD under the guidance of Dr. Sanjay Nigam and Dr. Shu Chien, in which his main focus of study is the interaction between kidney functions and cellular metabolisms using methods of computational chemistry and data-mining. Prior to his Ph.D., Henry received B.S. degree in Bioengineering at UC Berkeley.
Theodore (Ted) Wing 溫庭宇
Surgical Training Specialist, Gradalis Inc.
As a Taiwanese licensed veterinarian, Ted obtained his Master’s Degree from Texas A&M University in 2013. He is currently working in Gradalis, Inc, a biopharmaceutical company developing individualized cancer biotherapeutics in phase 2-3 clinical studies in ovarian cancer, Ewing’s sarcoma, and checkpoint inhibitor combination trials in NSCLC and melanoma. He travels frequently to provide on-location aseptic procurement training to research coordinators, hospital staff, and surgeons. He also provides support in compliance with the FDA-CFR, the ICH-GCP, sponsor and local institutional operating procedures. He has worked with research groups including Mary Crowley Cancer Research Center and Cleveland Clinic.
Chih-Wei (Logan) Hsu
Imaging Specialist,
Optical Imaging and Vital Microscopy Core, Baylor College of Medicine
C-W Logan Hsu is an Imaging Specialist for Optical Imaging and Vital Microscopy Core (OIVM) at Baylor College of Medicine (BCM). Dr. Hsu received his MSs in Biochemical Engineering from NCTU (Taiwan) and in Technology Commercialization from McCombs School of Business at UT Austin, and Ph.D. in Biomedical Science from BCM. He works at OIVM to provide consultation, imaging experimental design, training, and image analysis across different imaging modalities for core users and collaborators. He is also actively developing 3D imaging protocols for visualizing the development and remodeling of cardiovascular system in early post-implantation mouse embryos.
Chien-Hung Yu 余建泓
Assistant Professor,
Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng-Kung University.
Dr. Chien-Hung Yu received B.S. (2002) and M.S. (2004) from Department of Agricultural Chemistry, National Taiwan University. He then moved to the Netherlands, where he earned his Ph.D. at Leiden University (2011). His graduate work focused on elucidating the molecular basis of ribosomal frameshifting-inducing mRNA secondary structures. In 2013, he joined Dr. Yi Liu's group at UT Southwestern Medical Center in Dallas to receive his postdoctoral training, where he continues his interests on protein translation. His postdoctoral work led to the discovery that there exists codes within the genetic codon impact protein translation processes and co-translational protein folding. In 2017, he will initiate his research group in the Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng-Kung University.
Yi-Cheng (Alex) Liu
Research Associate,
AROG Pharmaceuticals, Inc.
Alex graduated from Texas A&M University in 2013. He is currently working for Arog Pharmaceuticals, a Dallas-based clinical-stage biopharmaceutical company focusing on developing a tyrosine kinase inhibitor for various cancer treatment, including acute myeloid leukemia, soft tissue sarcoma and glioblastoma. He plays a role in facilitating opening phase III trials globally as well as managing relationships with investigators around the world. Previously, he was a research associate in University of Minnesota and Texas A&M University, supporting a wide range of projects in bioenergy and agriculture research. He was also a certified high school teacher in Taiwan before coming to the US.
Louise T. Chow
Theodore (Ted) Wing
Haofan (Eric) Peng
Larry Hsu
Kuen-Yuh Wu (吳焜裕)
Chih-Wei (Logan) Hsu
T. Arthur Chang
Wei-Chiang Chen
Diane D-S. Tang-Liu 湯丹霞
Joshua C. Chang (張嘉熙)
Yu-Chieh (Jack) Wang
Chou-Long Huang (黃朝龍)
Ian Y. Lian
Mark (Long-Rong) Kao 高龍榮
Henry C. Liu
Chien-Hung Yu 余建泓
Yi-Cheng Liu
bottom of page